Press Releases

New Studies Demonstrate 75% Myopia Management Efficacy with Chinese Children after 12 Months and No Evidence of Rebound Effect in North American Children for SightGlass Vision DOT™ Lenses

5 May 2025

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

9 December 2024

IMC 2024: Multiple Studies Reinforce SightGlass Vision 
Diffusion Optics Technology™ Efficacy¹ for Myopia Management

23 September 2024

SightGlass Vision Presents New Data at Academy ’23, Reinforcing Diffusion Optics Technology™ Myopia Control Impact

9 October 2023

SightGlass Vision Releases First White Paper on Diffusion Optics Technology™

20 September 2023

SightGlass Vision Reports Positive Four-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenses

5 September 2023

SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conference

6 June 2023

New SightGlass Vision Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology™ Spectacle Lenses at ARVO 2023

23 April 2023

SightGlass Vision Highlights New Myopia Control Spectacle Lens Technology at COOC 2023

12 April 2023

SightGlass Vision Spectacles Reduce Myopia Progression in Children, According to Three Year Clinical Study Data – AAO 2023

24 October 2022

SightGlass Vision Celebrates Major Milestones at IMC 2022

1 September 2022

SightGlass Vision Spectacles Control Myopia Progression for 6- and 7-Year-Olds, According to New Data Analysis – NCC2022

23 June 2022

Please note that our products are not available for sale or distribution in every country in the world.
Our products are not available for sale in the U.S.